Janice M. Mehnert, MD, a researcher in early-phase therapeutics and the treatment of skin malignancies, has been appointed Associate Director for Clinical Research at New York University Langone Health’s Perlmutter Cancer Center.
Dr. Mehnert was Associate Professor of Medicine at Robert Wood Johnson Medical School, where she was recruited in 2007 to develop a clinical and translational research program for the expert diagnosis and treatment of skin cancers. Since 2010, she has led a National Cancer Institute (NCI)-funded laboratory focused on developing new strategies for treating malignant melanoma by inhibiting autophagy and promoting apoptosis. Following her work in the early-phase trial space, Dr. Mehnert was appointed Regional Phase I Clinical Program Director at Rutgers Cancer Institute.
Janice M. Mehnert, MD
As a principal investigator of the KEYNOTE-028 trial, Dr. Mehnert and colleagues studied the effects of the immune checkpoint inhibitor pembrolizumab in multiple difficult-to-treat cancers, including thyroid and neuroendocrine tumors and small cell lung cancer. In addition to her laboratory, clinical, and administrative expertise, Dr. Mehnert has a decade-long history of collaboration with the NCI–Cancer Therapy Evaluation Program (CTEP) Early Therapeutic Clinical Trials Network. At Perlmutter Cancer Center, Dr. Mehnert will see patients with the Melanoma/Skin and Phase I Disease Management Groups. In her position as Associate Director for Clinical Research, she will lead Perlmutter Cancer Center to enhance its interactions with NCI-CTEP, expand early-phase trial activity in collaboration with the cancer center’s network sites in Brooklyn and on Long Island, and further develop a strong culture of clinical and translational investigation.
